Shares of Alembic Prescribed drugs Ltd rose greater than 2% on Monday, 18 August, after the corporate introduced that it had achieved last USFDA approval.
In its regulatory submitting, the corporate mentioned that it has acquired last approval from the US Meals and Drug Administration (USFDA) for its Abbreviated New Drug Software (ANDA) for Tretinoin Cream USP, 0.025%.
The product is a generic model of Bausch Well being’s 0.025% Retin-A Cream and is meant for the topical therapy of pimples vulgaris. In keeping with IQVIA analysis, the cream’s market dimension is predicted to be USD 94 million for the 12 months ending June 2025.
With this approval, Alembic’s whole ANDA approvals now stand at 224, with 202 last and 22 tentative. The enterprise acknowledged that the clearance strengthens its dermatology product portfolio in the US.
Alembic Prescribed drugs, a vertically built-in research-driven firm, manufactures and markets generic drugs worldwide. In its most up-to-date monetary outcomes, the corporate reported a 14.18% year-on-year progress in consolidated internet revenue to Rs 156.63 crore for Q1 June 2025, whereas income from operations elevated by 9.54% to Rs 1,710.72 crore.
At 1:48 pm, the shares of Alembic Pharma have been buying and selling 1.34% larger at Rs 969.75 on NSE.
The way forward for investing is right here!
Unicorn Indicators leverages superior AI know-how to give you highly effective market predictions and actionable inventory scans. Obtain the app right this momentand 10x your buying and selling & investing journey!
j4gfqi